“Migraine is an often disabling condition that affects an estimated 37 million people in the U.S.,” said Billy Dunn, M.D., acting director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, in an FDA press announcement. “Ubrelvy represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication. The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies.”
“I followed the productive year they had in 2019 with the launch of their digital asset markets, completion of their technology stack and the ability to secure a derivatives clearing organization (DCO) license,” Singh said about his new employer in a press release. “I look forward to joining the team of market professionals at ErisX and assisting in the next chapter of growth while managing the unique risks associated with a regulated digital asset platform.”
“Agilent launched an all-out legal assault on Twist and in the end, we not only survived, we thrived through the attack,” said Leproust in a press release. “We are pleased with the outcome and believe this settlement removes both the uncertainty and legal expense associated with any trial, and is in the best interest of all of our stakeholders.”
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.